JP2019516790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516790A5 JP2019516790A5 JP2019510737A JP2019510737A JP2019516790A5 JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5 JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cyclopentyl
- amino
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 4
- VFWVWPWWZVTJDG-UHFFFAOYSA-N thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C1=NC=C2SC(C(=O)N)=CC2=N1 VFWVWPWWZVTJDG-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- -1 (5- (4- (4- (methyl -d 3) piperazin-1-yl) piperidin-1-yl) pyridin-2-yl) amino Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333165P | 2016-05-07 | 2016-05-07 | |
| US62/333,165 | 2016-05-07 | ||
| PCT/CN2017/083162 WO2017193872A1 (en) | 2016-05-07 | 2017-05-05 | Certain protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516790A JP2019516790A (ja) | 2019-06-20 |
| JP2019516790A5 true JP2019516790A5 (https=) | 2020-04-09 |
| JP6927548B2 JP6927548B2 (ja) | 2021-09-01 |
Family
ID=60266275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510737A Active JP6927548B2 (ja) | 2016-05-07 | 2017-05-05 | ある種のタンパク質キナーゼ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10835535B2 (https=) |
| EP (1) | EP3452484B1 (https=) |
| JP (1) | JP6927548B2 (https=) |
| KR (1) | KR102374033B1 (https=) |
| CN (1) | CN109153686B (https=) |
| AU (1) | AU2017262155B2 (https=) |
| DK (1) | DK3452484T3 (https=) |
| ES (1) | ES2954148T3 (https=) |
| MX (1) | MX387648B (https=) |
| RU (1) | RU2738837C2 (https=) |
| TW (1) | TWI752026B (https=) |
| WO (1) | WO2017193872A1 (https=) |
| ZA (1) | ZA201808238B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN116836177A (zh) * | 2022-09-28 | 2023-10-03 | 锦州奥鸿药业有限责任公司 | 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途 |
| WO2025085360A1 (en) | 2023-10-16 | 2025-04-24 | The Board Of Regents Of The University Of Oklahoma | Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| AU2008242703B2 (en) | 2007-04-19 | 2011-08-18 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| DE102007038251A1 (de) | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| EP2217548A1 (en) | 2007-10-26 | 2010-08-18 | Concert Pharmaceuticals Inc. | Deuterated darunavir |
| EP2215094B1 (en) * | 2007-11-15 | 2016-01-27 | YM BioSciences Australia Pty Ltd | N-containing heterocyclic compounds |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| FR2988722B1 (fr) * | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| DK3149008T3 (en) * | 2014-05-28 | 2019-04-01 | Shanghai Fochon Pharmaceutical Co Ltd | Specific protein kinase inhibitors |
| CN105294737B (zh) * | 2014-07-26 | 2019-02-12 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
-
2017
- 2017-05-05 KR KR1020187034605A patent/KR102374033B1/ko active Active
- 2017-05-05 RU RU2018143284A patent/RU2738837C2/ru active
- 2017-05-05 JP JP2019510737A patent/JP6927548B2/ja active Active
- 2017-05-05 EP EP17795490.6A patent/EP3452484B1/en active Active
- 2017-05-05 ES ES17795490T patent/ES2954148T3/es active Active
- 2017-05-05 MX MX2018013573A patent/MX387648B/es unknown
- 2017-05-05 TW TW106114998A patent/TWI752026B/zh active
- 2017-05-05 DK DK17795490.6T patent/DK3452484T3/da active
- 2017-05-05 WO PCT/CN2017/083162 patent/WO2017193872A1/en not_active Ceased
- 2017-05-05 AU AU2017262155A patent/AU2017262155B2/en active Active
- 2017-05-05 CN CN201780028206.7A patent/CN109153686B/zh active Active
- 2017-05-05 US US16/099,218 patent/US10835535B2/en active Active
-
2018
- 2018-12-06 ZA ZA2018/08238A patent/ZA201808238B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516790A5 (https=) | ||
| JP2017504635A5 (https=) | ||
| JP2017519781A5 (https=) | ||
| RU2018143284A (ru) | Некоторые ингибиторы протеинкиназы | |
| JP2017525668A5 (https=) | ||
| JP2013528204A5 (https=) | ||
| NZ627709A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
| HRP20220414T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| JP2017502940A5 (https=) | ||
| JP2017514830A5 (https=) | ||
| JP2017521407A5 (https=) | ||
| JP2014504622A5 (https=) | ||
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| JP2012501312A5 (https=) | ||
| HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
| HRP20181008T1 (hr) | Terapeutski aktivni pirazolo-pirimidin derivati | |
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2019512535A5 (https=) | ||
| RU2016134751A (ru) | Соединения | |
| JP2012513416A5 (https=) | ||
| MX2021000095A (es) | Derivados de aril-n-arilo para el tratamiento de una infeccion por virus de acido ribonucleico (arn). | |
| JP2016028076A5 (https=) | ||
| JP2014500296A5 (https=) |